Response to Letter by Borja et al
We thank Dr Borja and his coauthors for alerting us to the data from trials on triflusal. These trials demonstrate the safety of triflusal, but have not shown any superiority over aspirin for noncardioembolic stroke or transient ischemic attack. We agree that the NASPEAF trial reported intriguing results; however, because of space limitations, it was not reviewed. At present, triflusal is not an approved agent for stroke prevention in atrial fibrillation in North America; therefore, it was not considered for inclusion in our recommendations. We hope that more evidence will become available on triflusal to include in future updated recommendations.